InvestorsHub Logo
Followers 28
Posts 9426
Boards Moderated 0
Alias Born 05/30/2012

Re: JNdouble1 post# 291420

Monday, 05/23/2022 1:07:15 PM

Monday, May 23, 2022 1:07:15 PM

Post# of 328007
Viva La Andy !!
Viva La KELLY !!
Viva La KEITH !!
Viva La SREE !!
Viva La RICHARD !!
BIEL$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BioElectronics Corp. (OTCPINK: $BIEL) Powerful Reversal Brewing as Pain Management Pioneer Launches RecoveryRx into Mexico & Spain

Quote:
BioElectronics Corp. (OTCPINK: BIEL) recently hit lows of $0.0005 and accumulation has begun in earnest in recent days in red overall markets. Microcapdaily has been reporting on BIEL for years and covered them in triple digits back in November shortly after the Company received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). Biotech’s are among the most explosive stocks in penny stocks and BIEL has a significant gap to fill from $0.038 highs of February 2021. The stock has a large investor following that will buy in significantly as soon as BIEL makes a significant reversal.

BIEL has been busy since executing the OEM agreement with KT Health in December; the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. More recently BIEL’s distribution partner in Mexico received authorization from Mexican FDA (Cofepris), which allows for the importation of the RecoveryRx® device into Mexico. Novro Med S.A. de C.V. has contracted for the exclusive distribution rights for RecoveryRx® in Mexico and it is expected that they will receive their initial stocking order during the 2nd quarter, 2022. The Company also entered into a distribution agreement with Madrid / Spain based PRIM Group for the distribution of its RecoveryRx device throughout Spain. As per latest filings BIEL is topping well over $100,000 a month in sales.


https://microcapdaily.com/bioelectronics-corp...ico-spain/






https://www.bielcorp.com/bioelectronics-corporation-reports-double-digit-quarterly-sales-growth-kt-health-and-djo-launches-outpacing-forecasts/


https://www.prnewswire.com/news-releases/kt-tape-launches-kt-recovery-wave-301232376.html

https://www.bielcorp.com/bioelectronics-corporation-announces-substantial-increase-in-4th-quarter-2020-revenue-major-convertible-debt-holders-agree-to-forego-interest-in-2021/

https://www.bielcorp.com/bioelectronics-actipatch-therapy-to-be-marketed-by-donjoy-advantage/

https://www.bielcorp.com/bioelectronics-announces-fda-market-clearance-for-over-the-counter-treatment-of-musculoskeletal-pain/